Eli Lilly and Company (LLY)vsArcus Biosciences Inc (RCUS)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
RCUS
Arcus Biosciences Inc
$24.13
-2.70%
HEALTHCARE · Cap: $3.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 26288% more annual revenue ($65.18B vs $247.00M). LLY leads profitability with a 31.7% profit margin vs -142.9%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
RCUS
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+88.5%
Fair Value
$184.95
Current Price
$24.13
$160.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Conservative balance sheet, low leverage
Revenue surging 26.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Weak financial health signals
ROE of -63.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : RCUS
The strongest argument for RCUS centers on Debt/Equity, Revenue Growth. Revenue growth of 26.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : RCUS
The primary concerns for RCUS are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
RCUS carries more volatility with a beta of 0.86 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 30/100), backed by strong 31.7% margins and 42.6% revenue growth. RCUS offers better value entry with a 88.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Arcus Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?